📰 Commodore Capital News
Page 9 - Commodore Capital News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Commodore Capital. Real-time updates on events, politics, business and more.
April 16, 2023
Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Rating) – Investment analysts at Lifesci Capital issued their Q1 2023 earnings estimates for Akero Therapeutics in a research note issued to investors on Tuesday, April 11th. Lifesci Capital analyst P. Dolezal expects that the company will post earnings of ($0.58) per share for the quarter. Lifesci Capital has […]
April 6, 2023
Shares of BELLUS Health Inc. (NASDAQ:BLU – Get Rating) shot up 6.3% on Thursday . The company traded as high as $6.89 and last traded at $6.87. 387,856 shares changed hands during trading, a decline of 41% from the average session volume of 662,235 shares. The stock had previously closed at $6.46. Analyst Upgrades and […]
March 1, 2023
Gide has advised the financial advisors SVB Securities, LifeSci Capital et Bryan, Garnier & Co in connection with the successful pricing of an oversubscribed Abivax €130 million financing with high-quality U.S. and European biotech specialist investors, by way of a reserved capital increase. This is the largest private placement of a biotech company listed only on Euronext Paris.
February 22, 2023
EQS-News: ABIVAX / Key word(s): Capital IncreaseAbivax announces successful oversubscribed EUR 130M cross-over financing at market price with top-tier US and European biotech investors 22.02.2023 / 18:05 CET/CESTThe issuer is solely responsible for the content of this announcement.NOT FOR DISTRIBUTION IN OR INTO THE...
February 22, 2023
NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR TO U.S. PERSONSAbivax announces successful oversubscribed EUR 130M cross-over financing at market price with top-tier US
December 7, 2022
First patient dosing enables closing of $100 million PIPE financing and drawdown of $20 million term loan trancheMINNEAPOLIS, MN / ACCESSWIRE / December 7, 2022 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage
October 14, 2022
Concurrent with the merger, Enliven plans to raise $165 million in a private financing, and the joint company is expected to have $300 million in cash and cash equivalents.
October 10, 2022
NEW YORK, Oct. 10, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX) (Immunic or the Company), a clinical-stage biopharmaceutical company deve...
October 7, 2022
The drugmaker announced a $75 million public offering.
August 18, 2022
Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Rating) Director Simon N. Pimstone sold 33,942 shares of the company’s stock in a transaction dated Monday, August 15th. The stock was sold at an average price of $37.76, for a total transaction of $1,281,649.92. Following the transaction, the director now owns 58,058 shares in the company, valued at […]